Minuteman Therapeutics
Minuteman Therapeutics develops oncolytic viruses engineered against an individual patient's tumour, matching the virus to the biology of that person's cancer.
Overview
Oncolytic viruses infect and kill cancer cells and alert the immune system to them; talimogene laherparepvec is the approved example. Minuteman's stated approach is personalised: an oncolytic virus designed against the individual patient's tumour rather than one product for all. It is an Even One Ventures portfolio company with no published trials.
Funding
All startupsSimilar pages
not linked directly; found by shared links- CompanyRelit Biosciences
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyEcho Immune
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyRanata Therapeutics
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyYuga Bio
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyInvocata
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyValius Sciences
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyKernis Health
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyPalitra Bio
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.